Aspirin may reduce elevated risk of cancer caused by obesity

the ONA take:

Taking aspirin regularly can negate the increased the risk for developing colorectal cancer in patients with Lynch syndrome, according to a new study published online ahead of print in the Journal of Clinical Oncology has shown.

"This is important for people with Lynch Syndrome but affects the rest of us too. Lots of people struggle with their weight and this suggests the extra cancer risk can be cancelled by taking an aspirin," Professor Sir John Blum, professor of Clinical Genetics at Newcastle University in Leeds, UK, said.

For the study, researchers enrolled 937 patients with Lynch syndrome and randomly assigned them to receive aspirin 600 mg per day or placebo, plus resistant starch 30 g per day or placebo. Results showed that during a median follow-up of 55.7 months, the risk of colorectal cancer was nearly 2.5 times higher for overweight participants than for underweight and normal-weight participants.

Obese patients had a 1.77 times increased risk of Lynch syndrome-related cancer compared with normal-weight participants.

The findings suggest that overweight patients with Lynch syndrome are likely to benefit from obesity prevention and/or regular aspirin.

Taking aspirin regularly can negate the increased the risk for developing colorectal cancer in patients with Lynch syndrome.

Research has shown that a regular dose of aspirin reduces the long-term risk of cancer in those who are overweight in an international study of people with a family history of the disease. The study, conducted by researchers at Newcastle University and the University of Leeds, UK, is published today in the Journal of Clinical Oncology.